PSCA (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:8000, HGNC:9500, MIM:602470, NM_005672, NP_005663, NR_033343, PRO232, PSCA, prostate stem cell antigen

Omim:OMIM:602470

Id:ENSG00000167653

Hgnc:HGNC:9500

Entrez:8000

Ensembl:ENSG00000167653

Description:prostate stem cell antigen

This gene encodes a glycosylphosphatidylinositol-anchored cell membrane glycoprotein. In addition to being highly expressed in the prostate it is also expressed in the bladder, placenta, colon, kidney, and stomach. This gene is up-regulated in a large proportion of prostate cancers and is also detected in cancers of the bladder and pancreas. This gene includes a polymorphism that results in an upstream start codon in some individuals; this polymorphism is thought to be associated with a risk for certain gastric and bladder cancers. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2010]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View PSCA's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with PSCA.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using PSCA.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for PSCA.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with PSCA.

Results found

Linked to

	Label	Description
	GSE216043 7 V 9 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216988 GSE216989 decitabine 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE139178 GDC-0068 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE192860 0 V 1 TRIFLUOPERAZINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE169617 azacitidine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE228017 parthenolide 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 3 V 0 ISOX HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE166315 1 V 0 DOCETAXEL MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS

GSE216043 7 V 9 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE162892 ISOX 3 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE216988 GSE216989 decitabine 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE139178 GDC-0068 3 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE192860 0 V 1 TRIFLUOPERAZINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE169617 azacitidine 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE228017 parthenolide 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE162892 3 V 0 ISOX HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE166315 1 V 0 DOCETAXEL MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.